Insulet (PODD) Net Cash Flow Growth (3y) (2013 - 2026)
Insulet (PODD) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -48.90% |
| 10 | Insulet | 11.52 Bn | 11.04 Bn | 529.10 Mn | -63.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.29% |
| Dec 31, 2025 | 6.99% |
| Sep 30, 2025 | -176.63% |
| Jun 30, 2025 | -358.86% |
| Mar 31, 2025 | 82.00% |
| Dec 31, 2024 | 43.03% |
| Sep 30, 2024 | 163.80% |
| Jun 30, 2024 | 26.05% |
| Mar 31, 2024 | 37.05% |
| Dec 31, 2023 | -41.22% |
| Sep 30, 2023 | -22.71% |
| Jun 30, 2023 | -65.31% |
| Mar 31, 2023 | -80.05% |
| Dec 31, 2022 | 37.07% |
| Sep 30, 2022 | -60.28% |
| Jun 30, 2022 | 29.93% |
| Mar 31, 2022 | -92.97% |
| Dec 31, 2021 | -74.36% |
| Sep 30, 2021 | 34.52% |
| Jun 30, 2021 | 36.27% |